Pre-order Enquiry
Request Free Sample
Global Glycated Albumin Sales Market Report 2020
SKU ID : QYR-16610700 | Publishing Date : 23-Oct-2020 | No. of pages : 144
Request Sample
Request Customization
Check Discounts
Diabetes afflicts an increasing number of people worldwide each year. Proper blood glucose control is essential in preventing complications associated with diabetes, such as neuropathy, nephropathy and retinopathy.
Glycation is the result of a sugar molecule, such as fructose or glucose, bonding to a protein or lipid molecule without the controlling action of an enzyme. It is a haphazard process that impairs the functioning of biomolecules. The high levels of glucose present in diabetes meatus results in increased glycation of all proteins, including, albumin. Measurement of the amount of the glycation reaction resulting from the combination of glucose with free amino groups in proteins present in the blood is used to monitor the level of glucose that has generally been present in body fluids over a preceding period.
Thus serum glycated albumin assay can be used to determine the current level of glycation of albumin, the most abundant plasma protein. Hence, the gycated albumin assay may be used as a marker of glycemic control in diabetes and reflects glycemic control over the precious 2 to 4 weeks.
Glycated albumin industry is relatively concentrated, manufacturers are mostly in the Europe, North America, Japan and China. Among them, Japan output value accounted for more than 81.90% of the total output value of global glycated albumin. Asahi Kasei Pharma is the world leading manufacturer in global glycated albumin market with the market share of 79.81% in 2015, in terms of revenue.
Market Analysis and Insights: Global Glycated Albumin Market
The global Glycated Albumin market size is projected to reach US$ 528.9 million by 2026, from US$ 396.9 million in 2020, at a CAGR of 4.9% during 2021-2026.
Global Glycated Albumin Scope and Market Size
The global Glycated Albumin market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glycated Albumin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Glycated Albumin market is segmented into
Glycated Albumin (Human)
Glycated Albumin (Animal)
Segment by Application, the Glycated Albumin market is segmented into
Hospitals and Clinics
Laboratories
The Glycated Albumin market is analysed and market size information is provided by regions (countries). Segment by Application, the Glycated Albumin market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Glycated Albumin market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Glycated Albumin business, the date to enter into the Glycated Albumin market, Glycated Albumin product introduction, recent developments, etc.
The major vendors covered:
Asahi Kasei Pharma
DIAZYME
Abnova
LifeSpan
Exocell
BSBE
Medicalsystem
Maccura
Leadman
Simes Sikma
NINGBO PUREBIO
Glycation is the result of a sugar molecule, such as fructose or glucose, bonding to a protein or lipid molecule without the controlling action of an enzyme. It is a haphazard process that impairs the functioning of biomolecules. The high levels of glucose present in diabetes meatus results in increased glycation of all proteins, including, albumin. Measurement of the amount of the glycation reaction resulting from the combination of glucose with free amino groups in proteins present in the blood is used to monitor the level of glucose that has generally been present in body fluids over a preceding period.
Thus serum glycated albumin assay can be used to determine the current level of glycation of albumin, the most abundant plasma protein. Hence, the gycated albumin assay may be used as a marker of glycemic control in diabetes and reflects glycemic control over the precious 2 to 4 weeks.
Glycated albumin industry is relatively concentrated, manufacturers are mostly in the Europe, North America, Japan and China. Among them, Japan output value accounted for more than 81.90% of the total output value of global glycated albumin. Asahi Kasei Pharma is the world leading manufacturer in global glycated albumin market with the market share of 79.81% in 2015, in terms of revenue.
Market Analysis and Insights: Global Glycated Albumin Market
The global Glycated Albumin market size is projected to reach US$ 528.9 million by 2026, from US$ 396.9 million in 2020, at a CAGR of 4.9% during 2021-2026.
Global Glycated Albumin Scope and Market Size
The global Glycated Albumin market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glycated Albumin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Glycated Albumin market is segmented into
Glycated Albumin (Human)
Glycated Albumin (Animal)
Segment by Application, the Glycated Albumin market is segmented into
Hospitals and Clinics
Laboratories
The Glycated Albumin market is analysed and market size information is provided by regions (countries). Segment by Application, the Glycated Albumin market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape
and Glycated Albumin Market Share AnalysisGlycated Albumin market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Glycated Albumin business, the date to enter into the Glycated Albumin market, Glycated Albumin product introduction, recent developments, etc.
The major vendors covered:
Asahi Kasei Pharma
DIAZYME
Abnova
LifeSpan
Exocell
BSBE
Medicalsystem
Maccura
Leadman
Simes Sikma
NINGBO PUREBIO
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
